Peel Hunt Reaffirms “Buy” Rating for Silence Therapeutics (LON:SLN)

Share on StockTwits

Peel Hunt restated their buy rating on shares of Silence Therapeutics (LON:SLN) in a research report report published on Wednesday, July 18th.

Shares of Silence Therapeutics remained flat at $GBX 114.75 ($1.49) during trading hours on Wednesday, according to MarketBeat. The company had a trading volume of 601 shares, compared to its average volume of 13,380. Silence Therapeutics has a 12 month low of GBX 71.88 ($0.93) and a 12 month high of GBX 254.75 ($3.30).

About Silence Therapeutics

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases.

Recommended Story: What is the NASDAQ Stock Market?

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply